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Abstract. Quinine derived thiourea catalysed the 
enantioselective addition of 4-substituted pyrazolones to 
isatin-derived ketimines, providing a variety of amino 
oxindole-pyrazolone adducts containing congested vicinal 
tetrasubstituted stereocenters with excellent outcomes (up 
to 98% yield, >20:1 dr and 98% ee). 
Keywords: asymmetric catalysis; ; pyrazolones ; isatin-
derived ketimines; organocatalysis; quaternary 
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The catalytic enantioselective synthesis of building 
blocks with contiguous quaternary stereocenters is a 
hot topic because of the prevalence of such structural 
motifs in natural and bioactive compounds.[1] This goal 
represents one of the greatest challenges in organic 
synthesis, due to the steric congestion making difficult 
the selective C-C bond formation.[2] In this context, the 
efficient assembly of multifunctionalised heterocyclic 
compounds containing quaternary stereocenters is of 
great importance. For example, the 3-substituted 3-
amino-2-oxindole[3] skeleton bearing a tetra-
substituted stereogenic center at the 3-position is a 
privileged heterocyclic structure present in many 
biologically active natural products and 
pharmaceutical drugs (SSR149415,[4] AG-041R[5] or 
NITD609[6]). The addition of nucleophiles to isatin-
derived ketimines is one of the most straightforward 
methodology established for synthesis of chiral 3-
substituted 3-amino-2-oxindole.[3b,7] However, only 
few succesful examples have been described for the 
assembly of vicinal tetrasubstituted stereogenic 
centers using isatin-derived ketimines as 
electrophiles.[8] On the other hand, the pyrazolone is a 
prominent heterocycle,[9] which exists in plenty of 
biologically active coumpounds with antiinflamatory, 
antiviral, antitumor or antibacterial properties;[10] 
moreover, pyrazol-3-ones are present in numerous 
pharmaceutical compounds (edaravone,[11] 
metamizole[12] or remogliflozin etabonate[13]). Despite 
the importance of pyrazolone derivatives, the 
examples of the synthesis of optically pure 4,4-
disubstituted-3-pyrazolones are scarce.[14,15] Very 
recently Yuan,[15a] Feng,[15b-d] Rios[15e-f] and Gong[15g] 
described the enantioselective additions of 4-
substituted pyrazolone derivatives to different 
electrophiles, for the synthesis of pyrazolone bearing a 
chiral quaternary stereocenter. However, the addition 
of 4-substituted pyrazolone derivatives to ketimines 
has not been described.[16] 
Herein, we wish to report the addition of 4-substituted 
pyrazolones to isatin-derived ketimines using a 
bifunctional organocatalyst, leading to chiral 
heterocyclic compounds containing both amino 
oxindole and pyrazolone moieties bearing vicinal 
quaternary stereocenters with good yields and 
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Figure 1. Construction of vicinal tetrasubstituted 
stereogenic centers in the addition of pyrazol-3-ones to 
isatin-derived ketimines. 
Our initial studies were focused on the addition of 4,5-
dimethyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one 
(2a) to isatin-derived N-Boc ketimine 1a in the 
presence of a series of bifunctional organocatalysts.[17]  
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2 Full 5:1 18 9 
2 Cat-2 
(5 %) 
2 98 6:1 66d 15d 
3 Cat-3 
(5 %) 
1 Full 2:1 27 49d 
4 Cat-4 
(5 %) 
1 Full >20:1 96 n.d. 
5 Cat-5 
(5 %) 
1 Full >20:1 95 n. d. 
6 Cat-6 
(5 %) 
1 Full 4:1 91d 63d 
7e Cat-4 
(5 %) 
2 Full 8:1 84 18 
8f Cat-4 
(5 %) 
2 Full 18:1 96 n. d. 
9 Cat-4 
(2 %) 
1,5 Full 17:1 95 n. d. 
10 Cat-4 
(1 %) 
1,5 Full 17:1 96 n. d. 
11g Cat-4 
(1 %) 
1,5 Full >20:1 98 n. d. 
a) 1a (0.05 mmol), 2a (0.051 mmol) and catalyst (x mol%) 
in 1 mL of toluene at rt. b) Determined by 1H NMR. c) 
Determined by HPLC using chiral stationary phase. d) 
Opposite enantiomer was obtained. e) CH2Cl2 was used as 
solvent. f) Et2O was used as solvent. g) The reaction was 
performed at 0 ºC. Ar=3,5-(CF3)2-C6H3.  
As shown in Table 1, when 5 mol% of quinine (Cat-
1) was used in toluene, full conversion was obtained 
within 2 hours, providing compound 3a in 5:1 
diastereomeric ratio (d.r.) and poor enantiomeric 
excesses for both diastereoisomers (entry 1). 
Quinidine (Cat-2) afforded 3a with better d.r. (6:1), 
and enantiomeric excesses (66% ee for the major 
diastereoisomer, entry 2). Cupreine derivative Cat-3, 
could catalyse the reaction but product 3a was 
obtained with poor diastereo- and enantioselectivities 
(entry 3). Quinine derived thiourea Cat-4 and quinine 
derived squaramide Cat-5, exhibited excellent 
reactivity with high stereocontrol, giving full 
conversion to product 3a with excellent d.r. (>20:1) 
and high enantiomeric excess (96% ee with Cat-4 and 
95% ee with Cat-5, entries 4 and 5 respectively). With 
commercially available Takemoto’s catalyst (Cat-6) a 
decreased in the diastereoselectivity was observed (4:1 
d. r.; entry 6). Different solvents were tested with Cat-
4, achieving lower selectivities (entries 7 and 8). A 
reduction in the catalyst loading was then investigated 
(entries 9 and 10), observing similar 
enantioselectivities but slightly lower diasteroisomeric 
ratios. Finally, by using 1 mol% of Cat-4 in toluene at 
0 °C (entry 11), product 3a was gained with excellent 
stereoselectivity (>20:1 dr and 98% ee). 
Having established the optimal reaction conditions 
(entry 11, Table 1) that are similar to the reported in 
the work of Wennemers for the addition of 
monothiomalonate to isatin-ketimines,8c the scope of 
the reaction was evaluated (Scheme 1). First, N-
substitution of oxindole nitrogen was investigated 
(Scheme 1, 3a-3f).  Groups such as benzyl, methyl, 
allyl, methoxymethyl or phenyl were well tolerated, 
and the corresponding products were obtained with 
high diastereo- and excellent enantioselectivities. 
However, when the nitrogen was protected with an 
ethoxycarbonyl group, the corresponding product 3f 
was obtained with lower diastereo- and 
enantioselectivity. Meanwhile when a tosyl protecting 
group was used, very poor reactivity and 
diastereoselectivity was observed and the products 
were obtained as a nearly racemic mixtures. Next, the 
effect of substitution in the benzene ring of the N-
benzyl protected isatin ketimines was studied (3g-3l). 
Different electron-donating (Me or MeO) or electron-
withdrawing (Cl or NO2), were tolerated at the 5 
position of the isatin-derived ketimine, affording the 
corresponding products with good yields and high 
stereocontrol. Moreover, ketimines with substituents 
at 6 or 7 positions reacted smoothly, providing the 
tertiary amines 3 with good results. Next, the substrate 
scope with respect to 4-substituted pyrazolones (ethyl 
or benzyl) was evaluated (3m-3o) obtaining good 
values of diastereo- and enantioselectivity, although a 
decrease in the reactivity was observed. When 4-
methyl-2,5-diphenyl-pyrazolone was used as a 
nucleophile, poor d.r. and ee values were observed 
(3p) with Cat-4, although the diastereoselectivity 
could be increased with quinine derived squaramide 
(Cat-5). Finally, the reaction with 2,4,5-trimethyl-
pyrazolone, gave compound 3q with a good d.r. and 
moderate enantioselectivity. Nevertheless, when Cat-
5 was used, the product 3q was afforded with better d.r. 




Scheme 1. Scope of the addition of pyrazolones to isatin 
derived N-Boc ketimines: 1 (0.05 mmol), 2 (0.051 mmol) 
and Cat-4 (1 mol%) in 1 mL of toluene at 0 °C. Isolated 
yields after column chromatography. Diastereoselectivities 
were determined by 1H NMR of the crude reaction mixture. 
Enantioselectivities of the major diastereoisomer were 
determined by HPLC using chiral stationary phase. a) 2 
mol% of catalyst was used. 
The absolute configuration of the two stereogenic 
centers in compound 3i was determined to be (3R, 4’S) 
on the basis of X-ray crystallographic analysis (Figure 
2); the configuration of the rest of the products 3 was 
assigned on the assumption of a uniform mechanistic 
pathway.[18]. 
 
Figure 2. X-ray crystal structure of 3i. 
A plausible transition-state model is depicted in 
Scheme 2. The thiourea acts as bifunctional 
organocatalyst responsible for the preorientation and 
the activation of the substrates. While the isatin 
derived N-Boc ketimine moiety is activated upon 
formation of hydrogen bonds between the N-Boc 
group and the thiourea, the pyrazolone undergoes 
nucleophilic activation by hydrogen bonding with the 
quinuclidine moiety of the catalyst.[19] The 4-
substituted pyrazolone will be directed to the Re-face 
of the ketimine, thus accounting for the observed 
enantioselectivity.  
 
Scheme 2. Plausible transition-state model. 
In summary, we have described the enantioselective 
amino alkylation of 4-substituted pyrazolones with 
isatin-derived N-Boc ketimines catalysed by quinine 
derived thiourea organocatalysts. This approach 
provides a new methodology to synthesize optically 
active compounds containing vicinal tetrasubstituted 
stereocenters. The reaction shows a wide substrate 
scope for different N-Boc imines and 4-substituted 
pyrazolones. The present study extends the scope of 
the catalytic asymmetric amino alkylation with isatin 
 4
derived ketimines, providing a new class of amino 
oxindole derivatives.[3] Studies to further extend the 
scope of this reaction and evaluation of the biological 




A test tube containing ketimine 1 (0.1 mmol), pyrazolone 2 
(0.1 mmol) and thiourea Cat-4 (0.6 mg, 0.001 mmol) was 
purged with N2. Then, 1.0 mL of toluene was added and the 
mixture stirred at 0 ºC until the reaction was complete (TLC). 
Finally, the reaction mixture was directly poured to the 
column chromatograpy, using hexane:EtOAc (95:5) as 
eluent to afford product 3. 
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